Alvogen Korea Recognised at the Social Contribution Company Awards

Taipei, Taiwan and Seoul, South Korea, 29 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795, “Lotus” or the “Company”), a global pharmaceutical company headquartered in Taiwan, today announced that its wholly owned subsidiary, Alvogen Korea Co., Ltd. (“Alvogen Korea”), has been recognised at the Social Contribution Company Awards. Hosted by The Korea Economic Daily and sponsored by the Ministry of Employment and Labor, the awards recognise companies for their contributions to society across a range of categories.

Alvogen Korea was recognised for its contributions to environmental sustainability, support for future generations and care for vulnerable communities. The company has developed a broad range of corporate social responsibility initiatives centred on sustained employee participation and engagement with local communities.

These initiatives include tree-planting and marine ecosystem clean-up activities, lunchbox support for children, hygiene-product donations for young women facing financial difficulties, and employee volunteering with children in welfare facilities. Alvogen Korea also supports vulnerable communities through kimchi-sharing and bakery volunteer programmes, as well as family portrait sessions for single-mother families.

Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical, commented, “This recognition is a testament to the values we share across the Lotus group and our commitment to contributing positively to the communities in which we operate. We are proud to see Alvogen Korea and its employees recognised for the meaningful and sustained impact of their efforts. Their dedication demonstrates how our responsibility as a pharmaceutical company extends beyond providing medicines to supporting the broader health and well-being of society.”

Alvogen Korea, the Korean affiliate of Lotus Pharmaceutical, is one of the leading pharmaceutical companies in South Korea. The company has established strong positions across multiple therapeutic areas, including oncology and respiratory diseases, supported by extensive regulatory, marketing, and commercial capabilities. Through its broad portfolio of innovative and generic pharmaceutical products, Alvogen Korea is committed to improving access to high-quality treatment options and addressing the evolving needs of patients and healthcare professionals in Korea.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.